Business Wire

CA-DIALPAD-INC.

13.7.2021 12:12:10 CEST | Business Wire | Press release

Share
Dialpad Introduces TruCaaS to Business Communications With Launch of Dialpad Meetings for Single, Unified View

Dialpad Inc. , the industry leader in AI-powered communication and collaboration, today announced a truly unified approach to communications as a service. With the launch of Dialpad Meetings , the company is bringing its suite of products closer together across both business communications and customer engagement all on one unified, aesthetically cohesive platform with AI at its core.

Dialpad Meetings, formerly known as UberConference, adds new capabilities and establishes the Dialpad cloud communications platform as the one place for a truly unified Communications as a Service (TruCaaS) experience. With a TruCaaS solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.”

“At Dialpad, we believe when the right people come together anything is possible, and we want our brand to reflect this spirit of connection, collaboration and productivity in this new work-from-anywhere world,” said Craig Walker, CEO of Dialpad. “With today’s announcements, we are resetting expectations for communication experiences by building a business communication platform that is more beautiful, accessible, easy to deploy and easy to use — to help businesses of any size start, grow and scale.”

To bring the vision of TruCaaS to life, Dialpad is making the following capabilities available in its single, powerful platform:

  • Dialpad Meetings - The reliable UberConference technology customers know and love with a new look and set of features, including:
    • Video conferencing in HD quality for an in-the-room experience
    • Real-time Voice Intelligence (Vi™) provides live note-taking and automated transcription analysis, enabling attendees to focus on the conversation and ensure key moments are not missed.
    • Start and join Dialpad Meetings from any direct message, group message or channel within the Dialpad app. With Dialpad Meetings natively built into the platform, users are not required to manage multiple tabs or windows.
    • Emoji reactions and expressions build social connections with team members and provide feedback in real-time without interruptions.
  • Dialpad Channels - With one click, Dialpad Channels offers teams a “light lift” collaboration tool for quick text and/or audio conversations. By providing a space for informal chats, office hours and other water cooler conversations, Dialpad Channels combats video conferencing fatigue and reduces the need for formal 30-minute meetings.
  • Mobile screen sharing - Dialpad users can now share their screens on phone calls, whether everyone is a Dialpad user or not. No need to set an official meeting or jump onto a conference call to quickly resolve issues, collaborate on projects or do virtual walkthroughs.
  • Global availability - Dialpad Meetings is available through the Dialpad platform with connectivity in 49 countries.

After winning TechCrunch Disrupt NYC in 2012 for UberConference and igniting the work-from-anywhere movement, Dialpad is disrupting an industry built on legacy thinking. As part of this vision and aligned with its TruCaaS approach, Dialpad is launching its Work Beautifully campaign to further support and enable the hybrid workplace.

“Work Beautifully is the big-picture concept that the Dialpad brand and products aspire to. Not only do our talk, messaging, meetings and contact center products work beautifully, they enable others to work beautifully and collaboratively together,” said Morgan Norman, Chief Marketing Officer, Dialpad. “This bold, new visual identity honors Dialpad’s ground-breaking story, its history of innovation in communications, and is deeply rooted in the company’s core values: do the right thing, every voice matters, and experience first.”

The future of work is not restrained by employee or customer location, but is instead borderless; enabled by AI across every experience and seamlessly integrated into how people collaborate and create. Companies that embrace work-from-anywhere technology and empower employee and customer experiences with AI have a significant advantage over those that hold tight to outdated modes of communication, collaboration and productivity. Dialpad’s new release with integrated talk, messaging, meetings and contact center — all powered by AI across every experience — arrives at the right moment to help businesses thrive in this post-pandemic, work-from-anywhere world.

“Work Beautifully means simplicity and ease. Dialpad even takes notes and transcribes calls for us. It’s that flow state where work doesn’t feel like work anymore,” said Chad Pierce, Head of Building Technology, WeWork. “Dialpad makes it easy for our teams to stay close, wherever work finds them and frees our teams to collaborate from anywhere on the planet.”

Additional Resources

Social Networks:

About Dialpad

Dialpad is the leading cloud communications platform for talk, messaging, meetings and contact center in one beautiful app. Dialpad’s platform delivers AI across every employee and customer experience through real-time transcriptions, live agent coaching and sentiment analysis. More than 73,000 of the world’s most innovative businesses, including Domo, Motorola Solutions, Netflix, Splunk, Stripe, T-Mobile, Twitter, Uber and WeWork use Dialpad to connect and collaborate. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Visit www.dialpad.com for more information and to request a demo.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye